XML 30 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Commitments and Contingencies (Tables)
 9 Months Ended
Sep. 30, 2016
Commitments and Contingencies [Abstract]  
Summary of milestone payments
Milestones Payments 
    
(1) when Company initiates a Phase 1 Clinical Trial of a licensed product $750,000 
(2) when Company initiates a Phase 2 Clinical Trial of a licensed product  750,000 
(3) when Company initiates a Phase 3 Clinical Trial of a licensed product  1,500,000 
(4) Biological License Application filing with U.S. FDA  1,750,000 
(5) First commercial sale  1,500,000 
(6) after the first $10,000,000 in net sales  1,500,000 
Schedule of future minimum obligations on the lease

For the year ending September 30, 2017 $225,840 
For the year ending September 30, 2018  199,440 
For the year ending September 30, 2019  49,860 
Total $475,140